RNA: Avidity Enterprise Value to EBITDA Ratio
Avidity Biosciences (RNA) is implementing advanced RNA technologies via its AOC platform to combat muscular dystrophies. The company's capitalization is based on the commercialization of innovative drugs for the therapy of rare pathologies. A stable cash reserve guarantees R&D development without financial risks. The EV/EBITDA valuation multiple visualizes the business value dynamics, where 0.00 reflects the baseline level of the metric.
Analytical breakdowns for Avidity Biosciences
- stock price and consensus target price:
- market capitalization information:
- business book valuation details:
- debt and liquidity data:
Total Debt to Capital Avidity Biosciences|RNA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Avidity Biosciences, Inc.|RNA - Company Cumulative Debt|Debt to Book Capitalization Ratio Avidity Corp|RNA - Long-Term Debt Volume|Company Short-Term Debts Avidity Biosciences|Quick Ratio aviditybiosciences.com
- net income and valuation multiples indicators:
RNA - Net Financial Result|Projected Future Earnings Avidity Biosciences|RNA - Market Cap to Earnings|Future Price to Earnings Avidity Biosciences|RNA - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Avidity Corp|RNA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Avidity Biosciences|RNA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months aviditybiosciences.com|RNA - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Avidity Biosciences
Initial company analysis:RNA (Avidity)
Outsourcing the production of RNA drugs to contract partners minimizes capital expenditures for Avidity Biosciences (RNA), shifting the valuation focus toward operational efficiency. The company's EV/EBITDA ratio compares the total enterprise value with earnings before interest, taxes, depreciation, and amortization, allowing investors to identify an entry point at historical lows or recognize a systemic crisis through the analysis of this metric.
Analysis of competing companies
tempus.com - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio QGEN (Qiagen Corp)|IONS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA repligen.com|CRSP (CRISPR Therapeutics) - Enterprise Value to EBITDA Ratio|GeneDx Holdings - Business Value to Operating Income Before Depreciation|RARE (Ultragenyx Pharma) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BEAM|EV/EBITDA Multiple SRPT|Total Company Value to Operating Income Before Depreciation Ratio twistbioscience.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 10x Genomics TXG|Intellia Therapeutics Inc (NTLA) - Company Value to EBITDA|STOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio BioLife BLFS|WVE: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio mazetx.com|SION (Sionna Therapeutics) - EV/EBITDA Multiple|Prime Medicine Inc (PRME) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple TSHA|QURE - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx Holdings plc MGTX|RGNX: Enterprise Value to Operating Income Before Depreciation|Solid Biosciences - EV/EBITDA Multiple|Ocugen Inc (OCGN) - Enterprise Value to EBITDA Ratio|PACB: EV/EBITDA Multiple|Company Value to EBITDA Benitec Corp (BNTC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Design Therapeutics|rocketpharma.com (RCKT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 4D Molecular Therapeutics, Inc. (FDMT)|LXEO (lexeotx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT: Enterprise Value to Operating Income Before Depreciation|Silence Therapeutics - EV/EBITDA Multiple|PRQR - EV/EBITDA Multiple|CDXS: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Biotechnology, Inc.|Enterprise Value to Operating Income Before Depreciation MGX (Metagenomi Therapeutics)|EV/EBITDA Multiple DTIL|EV/EBITDA Multiple generationbio.com (GBIO)|EV/EBITDA Multiple BOLD (Boundless Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|IMNN: Enterprise Value to EBITDA Ratio|PHIO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MBIO: EV/EBITDA Multiple|RNAZ - Total Company Value to Operating Income Before Depreciation Ratio|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|Omega Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio OMIC (singulargenomics.com)|RGLS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Syros Pharmaceuticals Inc.|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TRACON Pharmaceuticals, Inc - Business Value to Operating Income Before Depreciation|UBX (Unity Biotechnology) - EV/EBITDA Multiple
